3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Classical hematology
1
Conditions
Healthy Participants
5
Neoplasms
4
Carcinoma, Non-Small-Cell Lung
3
Prostatic Neoplasms
2
Healthy Volunteers
2
Breast Neoplasms
2
cMET-dysregulated Advanced Solid Tumors
1
Venous Thrombosis
1
Venous Thromboembolism
1
Solid Tumor, Adult
1
Rectal Neoplasms
1
Pain
1
Ovarian Neoplasms
1
Neoplasm Metastasis
1
Multiple Endocrine Neoplasia Type 1
1
Melanoma
1
Liver Cirrhosis
1
Hypoalphalipoproteinemias
1
Healthy Adult Participants
1
Healthy
1
Endometrial Neoplasms
1
Drug-drug Interaction,SHR3680
1
Colorectal Neoplasms
1
Chronic Cough
1
Carcinoma, Squamous Cell
1
Advanced Solid Tumor
1
Advanced Non-small Cell Lung Cancer
1
Interventions
Dalteparin
7
apixaban
5
edoxaban
4
Rivaroxaban
3
Enoxaparin
3
Tinzaparin
2
Heparin
2
Fondaparinux
2
Dabigatran
2
calcium heparin
1
bemiparin
1
Warfarin
1
Ultrasonography, Doppler, Duplex
1
Rosuvastatin Calcium
1
Nadroparin
1
Heparin, Low-Molecular-Weight
1
Data Collection
1
Atorvastatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Venous Thrombosis
×
Rosuvastatin Calcium
×
Clear all
NCT01524653
2018-07-10
DISOLVE
University of Vermont
Phase 2
Completed
38 enrolled